Shareholders to Vote on Highly Dilutive Stellex Warrants and Expanded Equity Incentive Plan

summarizeSummary

TEAM INC is seeking shareholder approval for the issuance of common stock upon the exercise of highly dilutive warrants to Stellex Holder and to expand its equity incentive plan, both of which could lead to significant dilution. The filing also details a recent CEO transition.

check_boxKey Events

• Shareholder Vote on Stellex Warrant Issuance

  Shareholders will vote on Proposal Four to approve the issuance of common stock upon the exercise of warrants previously issued to Stellex Holder. These warrants, including initial and delayed draw tranches, could result in the issuance of up to 2,034,564 shares. If all these warrants were exercised, it would represent approximately 44.5% dilution to the current outstanding common stock. The initial exercise prices are $23.00 for Tranche A and $50.00 for Tranche B, with potential anti-dilution adjustments. Failure to obtain this approval would increase the dividend rate on the Series B Preferred Stock by 1%.

• Equity Incentive Plan Expansion Proposed

  Proposal Five seeks shareholder approval to increase the number of shares available for issuance under the 2018 Equity Incentive Plan by 250,000 shares. This would bring the total estimated shares available for new awards to 314,022, increasing the total overhang from 10.9% to 16.4%. This additional authorization represents approximately 5.47% potential dilution to the current outstanding common stock.

• CEO Transition Details

  The filing confirms Gary Hill's appointment as Chief Executive Officer effective February 1, 2026, following the termination of former CEO Keith D. Tucker on January 31, 2026. Mr. Tucker will receive a severance package including $1.125 million in base salary, his 2025 annual bonus, $19,000 for health benefits, and a $375,000 consulting fee for a 12-month period.

• Major Shareholder Support for Warrant Proposal

  Corre Holders, who collectively beneficially own approximately 35.1% of the company's voting power, have entered into a support agreement to vote in favor of the Stellex Warrant Shares Issuance Proposal, making its approval highly probable.

auto_awesomeAnalysis

This definitive proxy statement (DEF 14A) outlines critical proposals for the upcoming annual meeting, most notably seeking shareholder approval for the issuance of common stock upon the exercise of warrants previously issued to Stellex Holder. This approval is required because the potential dilution from these warrants exceeds 20% of outstanding common stock, and the exercise price of some warrants could be adjusted below the NYSE minimum price. Failure to obtain this approval would result in a 1% increase in the dividend rate on the Series B Preferred Stock, underscoring the importance of this vote for the company's financial structure. If all Stellex warrants were exercised, it would result in substantial dilution. Additionally, the company is seeking to increase the shares available under its equity incentive plan by 250,000, which would further contribute to potential dilution. These proposals are presented in the context of the company's previously reported deeper net loss and negative operating cash flow for 2025, and a recent CEO transition, indicating a period of significant financial and operational adjustments.